ASCO GI 2021

04–08 June 2021 | Virtual Meeting

It was great to hear Maartje Rohaan talk on the latest in TILs in #melanoma at #ESMOImmuno22!

If you want to hear more from her on this exciting topic, watch our exclusive interview with her below and more on http://VJOncology.com 🖥️

Watch: http://ow.ly/urkB50LXrMe

@myESMO

It’s day 2 of #ESMOImmuno22, and we’re excited to continue coverage of the latest in #ImmunoOnc!

Follow us @VJOncology or visit http://VJOncology.com for interviews with speakers, insightful podcasts and more 💻🔬

@myESMO #CellTherapy #Oncology #immunotherapy

At #SABCS22 we chatted to @DMBranco of @JulesBordet who told us about prognostic biomarkers for HR+/HER2- early #BreastCancer as well as unmet needs in palliative care

Interview coming soon to http://VJOncology.com!

@SABCSSanAntonio @AACR #BCsm #OncoAlert

🎥@GeukensTatjana & Maxim De Schepper of @Onco_KULeuven talked to us about inter-lesion heterogeneity of HER2-status in metastatic #BreastCancer, as well as the UPTIFER post-mortem tissue donation program!

@SABCSSanAntonio @AACR #BCsm #OncoAlert

Feeling so great to start general session 2 at #SABCS22 with these data on #TrastuzumabDeruxtecan in patients with advanced #HER2+ #BreastCancer progressing on #TDM1: comments are clearly not needed !!!

@SABCSSanAntonio @OncoAlert #bcsm @YaleBreast @YaleCancer

4
Load More

ASCO GI 2021

04–08 June 2021 | Virtual Meeting
View all videos

It was great to hear Maartje Rohaan talk on the latest in TILs in #melanoma at #ESMOImmuno22!

If you want to hear more from her on this exciting topic, watch our exclusive interview with her below and more on http://VJOncology.com 🖥️

Watch: http://ow.ly/urkB50LXrMe

@myESMO

It’s day 2 of #ESMOImmuno22, and we’re excited to continue coverage of the latest in #ImmunoOnc!

Follow us @VJOncology or visit http://VJOncology.com for interviews with speakers, insightful podcasts and more 💻🔬

@myESMO #CellTherapy #Oncology #immunotherapy

At #SABCS22 we chatted to @DMBranco of @JulesBordet who told us about prognostic biomarkers for HR+/HER2- early #BreastCancer as well as unmet needs in palliative care

Interview coming soon to http://VJOncology.com!

@SABCSSanAntonio @AACR #BCsm #OncoAlert

🎥@GeukensTatjana & Maxim De Schepper of @Onco_KULeuven talked to us about inter-lesion heterogeneity of HER2-status in metastatic #BreastCancer, as well as the UPTIFER post-mortem tissue donation program!

@SABCSSanAntonio @AACR #BCsm #OncoAlert

Feeling so great to start general session 2 at #SABCS22 with these data on #TrastuzumabDeruxtecan in patients with advanced #HER2+ #BreastCancer progressing on #TDM1: comments are clearly not needed !!!

@SABCSSanAntonio @OncoAlert #bcsm @YaleBreast @YaleCancer

4
Load More

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter